Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB)
Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed 6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance threatens the global effort to eradicate this disease. With limited options available, add...
Saved in:
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/155760 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed
6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance
threatens the global effort to eradicate this disease. With limited options available, additional novel
antibiotics are needed for the treatment of multidrug-resistant tuberculosis (MDR-TB). Telacebec is
a first-in-class antibiotic that targets the pathogen’s energy metabolism.
Areas covered: This paper provides an overview of the recent progress in the development and testing
of telacebec. We discuss published clinical data and examine the design and setup of its clinical trials.
We also offer insights on the therapeutic potential of telacebec and aspects of which should be
evaluated in the future.
Expert opinion: The first phase 2a trial showed a correlation between dosage and bacterial load in
patient sputum, which should be confirmed using a direct measurement method such as colonyforming
unit counting. Its clinical efficacy, favorable pharmacokinetic properties, low arrhythmogenic
risk, and activity against MDR-TB strains make telacebec a suitable candidate for further development.
Future clinical testing in combination with approved second-line drugs will reveal its full potential
against MDR-TB. Considering recent preclinical studies, we also recommend initiating clinical trials for
Buruli ulcer and leprosy. |
|---|